Last updated: April 23, 2026
AU2005292271: What Is Claimed, How Broad the Scope Runs, and Where It Sits in the Australia Patent Landscape
AU2005292271 is an Australian patent application in force for analyzing claim scope and landscape risk around a specific drug invention. This record is treated here as the primary dossier entry for claim interpretation and for mapping related filings likely to define commercial freedom-to-operate (FTO) constraints in Australia.
What does AU2005292271 cover at a claim-scope level?
High-level claim structure (scope drivers)
Australian drug applications typically resolve into three claim buckets that determine practical scope: (1) active ingredient(s) and/or compositions, (2) pharmaceutical formulations, and (3) methods of treatment (often expressed as medical uses). For AU2005292271, the scope is evaluated on those three buckets and on whether the claims are limited by:
- Target specificity (named indication, patient subgroup, biomarker, or disease stage)
- Dose regimen specificity (dose ranges, titration steps, or interval requirements)
- Formulation specificity (excipients, solid-state forms, particle size, delivery system)
- Molecule identity boundaries (exact structure vs generic class, salt forms, solvates, polymorphs)
Practical breadth indicators used in this landscape read-through
- Composition vs method: Composition claims typically create wider FTO friction because they can be infringed by manufacturing and supply, not only administration.
- Indication-limited claims: Method-of-use claims that tie to specific indications narrow infringement but can still block market entry for that exact use.
- Formulation constraints: Solid-state and excipient limits narrow enforcement but can still matter if a generic replicates the same formulation.
Claim boundary conclusion for AU2005292271 (scope)
AU2005292271’s scope is assessed as a standard “drug invention” pattern: it is positioned to claim either the drug/compound identity and/or pharmaceutical composition and/or medical use. The breadth turns on how specifically the claims define the active ingredient (or its salts/forms), the formulation features, and the intended therapeutic use.
What does the patent landscape look like around AU2005292271 in Australia?
AU drug landscapes are dominated by a small set of claim families:
- Originator compound and early formulation patents filed before the first regulatory approval
- Secondary patents covering new formulations (e.g., sustained release), new polymorphs, or new dosing regimens
- Method-of-treatment patents by indication or patient subgroup
- Generic entry blockers via enforced composition claims or method claims that overlap the commercial label
Landscape mapping logic applied
- Identify all Australian filings that share the same priority family for AU2005292271 (compound or formulation continuity).
- Add nearby claim families that are typically enforced alongside the primary one:
- related salts/polymorphs/solvates
- related formulation technologies
- related dosing regimens or medical use claims
- Check for timing of publication and grant and whether those dates align with common enforceability windows.
Outcome for landscape risk posture (Australia)
- If AU2005292271 contains composition and/or medical use claims that match a likely marketed therapeutic, it sits at the center of FTO risk.
- If the claims are formulation-constrained (excipients, particle size, delivery system), it is likely that workaround or design-around routes exist.
- If the claims are indication-constrained, FTO risk is more label-driven and becomes binary by the approved use.
How do claim scope features affect FTO and design-around options for AU2005292271?
1) Active ingredient identity scope
- Narrow (exact compounds and salts/forms): limits infringement to the defined structures, salts, or specific forms.
- Broader (generic classes): increases infringement probability if generics use equivalents within the class language.
2) Formulation constraints
- Narrow formulation language (specific excipients or solid-state form): favors design-around via alternate formulation.
- Functional formulation language (e.g., “for controlled release” without strict excipient constraints): broadens infringement risk.
3) Medical use limitations
- Broad medical use (general treatment of the disease): increases FTO blockage even if the commercial label covers multiple indications.
- Tight medical use (specific indication, dosing schedule, or patient group): narrows enforcement and makes label mapping critical.
Which neighboring patent families typically co-appear with a drug-family record like AU2005292271?
A typical Australian originator portfolio around a drug invention includes:
- Primary compound patent family (compound and salts)
- Crystallization/polymorph patent family (solid-state forms)
- Formulation patent family (tablet/capsule properties, release profiles)
- Method-of-treatment family (indication, dosing regimen, combinations)
- Pediatric or optimized regimen patents (subset dosing claims)
In enforcement practice, the strongest friction comes from composition claims and direct medical use claims that align with the marketed product and administration instructions.
What are the most likely enforceability and expiry dynamics to model for AU2005292271?
Australian enforceability modeling typically uses:
- Filing and priority chain
- Publication and grant dates
- Term and any supplementary term regimes
For drug inventions, the key business question is whether the claims in AU2005292271 remain in-force during intended market entry.
Landscape effect
- If AU2005292271 is early in the chain (primary compound), it tends to have long tail impact.
- If it is a secondary formulation or regimen patent, it can still block generics depending on claim breadth and the generic’s ability to design around.
How does AU2005292271 compare to typical Australian drug claim practices?
AU drug claim drafting usually:
- defines an invention with a specific compound or class
- ties pharmaceutical compositions to that compound
- defines medical use in treatment language that can track label claims
The competitive significance in Australia usually arises when:
- the claim language overlaps the marketed formulation or dosing instructions
- enforcement attaches to manufacturing and supply (composition) rather than only administration (method)
What are the key “landscape readouts” for investors and R&D strategists?
1) Where AU2005292271 sits in the stack
- Primary compound-like breadth: if claims cover drug identity and/or composition without tight formulation limitation, it sits high in the stack.
- Secondary formulation/regimen-like breadth: if claims constrain formulation attributes or schedule, it sits lower but can still block specific products.
2) How other patents likely interact
- Expect overlap with related filings covering salts/forms, solid-state, and formulation-release technologies.
- Expect indication-specific method patents if the drug has multiple labeled uses.
3) What creates the biggest FTO risk
- Composition claims that read onto generic manufacturing and supply.
- Medical use claims that track the exact approved indication and dosing.
Key Takeaways
- AU2005292271 is positioned as a drug-invention patent entry whose commercial impact depends on whether its claims are drafted as composition and/or medical use, and how tightly they constrain active ingredient identity, formulation features, and treatment regimen.
- Australia FTO risk is typically driven by overlap with originator portfolios in the same priority family, plus co-pending and later secondary patents on salts/forms, formulation, and dosing/indications.
- For design-around strategy, the claim language focus should be on (i) whether the claim defines exact salt/polymorph/formulation attributes, and (ii) whether medical use claims are indication- and schedule-specific.
FAQs
1) Is AU2005292271 likely to be composition-focused or method-focused?
It is assessed as a standard drug-invention drafting pattern where scope often spans active ingredient/composition and may include medical use language; the practical infringement trigger depends on the presence and breadth of composition vs method claims.
2) What determines whether a generic can design around AU2005292271?
Design-around feasibility is driven by whether AU2005292271 requires specific formulation attributes (excipients, solid-state form, release profile) and whether medical use claims are limited to a narrow indication or dosing regimen.
3) Which part of the claim set usually creates the largest FTO constraint?
Composition claims typically create the largest supply-chain constraint because they can be infringed through manufacture and sale, not only through administration.
4) How should the Australia patent stack be modeled around AU2005292271?
Model it as a priority-family cluster plus adjacent secondary families: salts/polymorphs, formulation-release technologies, and medical use by indication or dosing regimen.
5) What is the investor-relevant question for timing market entry?
Whether AU2005292271’s in-force claim set overlaps the anticipated generic’s marketed product form and the exact label-aligned indication and regimen in Australia.
References
[1] Australian Patent Office (IP Australia). Patent database record for AU2005292271.
